{"id":6007,"date":"2023-08-23T14:09:16","date_gmt":"2023-08-23T14:09:16","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realhearts-ceo-to-speak-at-china-heart-congress\/"},"modified":"2023-08-23T14:09:16","modified_gmt":"2023-08-23T14:09:16","slug":"realhearts-ceo-to-speak-at-china-heart-congress","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realhearts-ceo-to-speak-at-china-heart-congress\/","title":{"rendered":"Realheart\u2019s CEO to Speak at China Heart Congress"},"content":{"rendered":"
Press Release August 23, 2023<\/p>\n

Scandinavian Realheart\u2019s CEO Ina Laura Perkins has been invited to speak at the China Heart Congress, which will be held in Beijing on September 1-3, 2023. Ina Laura Perkins will speak about the company\u2019s total artificial heart that is being developed for patients with heart failure.<\/strong><\/div>\n

The conference, which is one of the largest in cardiovascular disease in the Asia\/Pacific region, is expected to gather over 8,000 participants. Ina Laura Perkins has been invited by one of China's leading heart surgeons, Mr. Shenshou Hu, President of Fuwai Hospital in Beijing. With an annual caseload of 15,000 cardiac surgeries and 50,000 interventional procedures, Fuwai Hospital is one of the world's largest cardiovascular clinics.<\/span><\/span><\/p>\n

\u201cCHC is an extraordinary opportunity for Realheart to create contacts and build awareness of our artificial heart in China and Southeast Asia. A better introduction to these markets is hard to imagine," says Ina Laura Perkins.<\/span><\/span><\/p>\n

In markets outside Europe and the US, such as China and Southeast Asia, Realheart intends to work with partners and distributors for marketing and sales of its total artificial heart. The markets are sizeable and comprise advanced treatments. The number of patients with heart failure is estimated at approximately 12 million in China and 9 million in Southeast Asia, which can be compared with 15 million in Europe and 6 million in the USA.<\/span><\/span><\/p>\n

During the autumn, Realheart intends to continue the work of identifying possible partners in the region and creating initial contacts with important parties.<\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart<\/em><\/span><\/span>\u00ae<\/span><\/span><\/span><\/em> TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation.\u00a0<\/em><\/span><\/span>A unique concept in the medical technology world.<\/span><\/span><\/span><\/em><\/p>\n<\/div>\n